Roche announced positive topline results from the Phase III REGENCY study, which evaluated Gazyva®/Gazyvaro® (obinutuzumab) in people with active...
Continued Investment in Technology & Flexible Capacity, Including New Fill/Finish Capabilities, Fortify the Global Gene Therapy Support Offer at Ascend...
Agarose Bead Technologies (ABT), a leading manufacturer of high-quality agarose resins, proudly announces the completion of a major expansion at its faci...
-Metabolomics Diagnostics, a deep-tech machine learning diagnostic platform developer, has developed an innovative test, PrePsia, to accurately predict t...
Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of nov...
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic One of the la...
New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a single patient sample on t...
The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the University of Oxford, UK and Harrington Discovery Institute at U...
QIAGEN chooses Bode Technology as its exclusive global commercial partner to accelerate use of GEDmatch PRO genealogy database in law enforcement and i...
4200 square-meter headquarter and manufacturing facility in Riom, France Consolidation of existing facilities with 150% additional manufacturing capacit...
The European Society for Medical Oncology (ESMO) 2024 Congress, held from September 13 to 17 in Barcelona, brought together global oncology experts to un...
Intas Pharmaceuticals announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive op...
AbbVie announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommen...
Upon authorization by the European Commission (EC), the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and o...
© 2025 Biopharma Boardroom. All Rights Reserved.
